UC DAVIS MEDICAL CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $177.9M
- Transactions
- 13,936
- Companies
- 40
- Average per transaction
- $12,765
Who reported the payments
| Merck | $17,059,298 |
| Takeda Pharmaceuticals U.S.A., Inc. | $15,745,667 |
| Pfizer | $12,939,091 |
| AbbVie | $9,241,186 |
| Genentech, Inc. | $9,070,817 |
| Gilead | $6,783,175 |
| Pharmacyclics LLC, An Abbvie Company | $6,645,796 |
| AstraZeneca | $5,400,799 |
| Seagen Inc. | $4,717,062 |
| Sarepta Therapeutics, Inc. | $4,168,190 |
| United Imaging Healthcare North America, Inc. | $4,068,238 |
| Eli Lilly | $3,943,569 |
| Janssen Research & Development, LLC | $3,439,539 |
| Amgen | $3,388,128 |
| GE HealthCare | $2,662,317 |
| E.r. Squibb & Sons, L.L.C. | $2,303,433 |
| Medicines360 | $2,275,521 |
| Sanofi US Services Inc. | $2,265,872 |
| Jazz Pharmaceuticals Inc. | $2,073,860 |
| Astrazeneca UK Limited | $2,046,942 |
| Medivation LLC. | $1,985,794 |
| Roche Diagnostics Operations, Inc. | $1,931,969 |
| Bristol Myers Squibb | $1,928,099 |
| Regeneron | $1,918,515 |
| Edwards Lifesciences | $1,887,249 |
| Boehringer Ingelheim | $1,795,015 |
| Incyte Corporation | $1,778,975 |
| Vertex | $1,748,432 |
| Abbott | $1,510,668 |
| Agilent Technologies, Inc. | $1,505,535 |
| Novartis | $1,437,285 |
| Biogen | $1,327,873 |
| Astellas Pharma Global Development | $1,289,402 |
| United Therapeutics Corporation | $1,221,243 |
| Masimo Corporation | $1,185,227 |
| Modernatx, Inc. | $1,155,064 |
| Intercept Pharmaceuticals, Inc. | $1,120,006 |
| Siemens Medical Solutions USA, Inc. | $1,067,775 |
| Novo Nordisk AS | $1,066,023 |
| Boston Scientific | $945,159 |